Related Experiment Videos
Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems
1Service d'Hématologie-Greffe de Moelle, Hôpital Saint Louis, Paris, France.
Blood Reviews
|July 20, 2002
Summary
Second malignancies are a growing concern after allogeneic stem cell transplantation. This review covers leukemia, lymphoma, and solid tumors, focusing on pathogenesis, diagnosis, and treatment.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Long-term survival after allogeneic hematopoietic stem cell transplantation (HSCT) has increased.
- Late effects, particularly second malignancies, are becoming clinically significant.
- Second malignancies post-HSCT are categorized into leukemia, lymphoma, and solid tumors.
Purpose of the Study:
- To review recent clinical and biological data on second malignancies following allogeneic HSCT.
- To focus on the pathogenesis, early diagnosis, and treatment of these transplant-related complications.
Main Methods:
- Literature review of recent clinical and biological data.
- Focus on leukemia, lymphoma, and solid tumors post-allogeneic HSCT.
Main Results:
- Second malignancies are an increasingly recognized late effect of allogeneic HSCT.
- Data on leukemia, lymphoma, and solid tumors are summarized.
- Emphasis on recent advancements in understanding and managing these complications.
Conclusions:
- Second malignancies are a critical late complication of allogeneic HSCT.
- Continued research into pathogenesis, early detection, and treatment is essential.
- This review provides an overview of current knowledge and future directions.